Shopping Cart
- Remove All
Your shopping cart is currently empty
Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $39 | In Stock | |
| 25 mg | $59 | In Stock | |
| 50 mg | $80 | In Stock | |
| 100 mg | $118 | In Stock |
| Description | Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity. |
| Targets&IC50 | PDGFRβ:5 nM (ki), FLK1:6 nM (ki) |
| In vivo | Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment[1]. |
| Synonyms | SU11654, PHA 291639E |
| Molecular Weight | 396.46 |
| Formula | C22H25FN4O2 |
| Cas No. | 356068-94-5 |
| Smiles | Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1 |
| Relative Density. | 1.293 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 2.4 mg/mL (6.05 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.